## JOC<sub>Note</sub>

## Concise Asymmetric Synthesis of (+)-CP-99,994 and (+)-L-733,060 via Efficient Construction of Homochiral syn-1,2-Diamines and syn-1,2-Amino Alcohols

Run-Hua Liu,<sup>†</sup> Kai Fang,<sup>‡</sup> Bing Wang,<sup>\*,†</sup> Ming-Hua Xu,<sup>\*,‡</sup> and Guo-Qiang Lin<sup>\*,†,‡,§</sup>

Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, Institutes of Biomedical Sciences, Fudan University, 138 Yixueyuan Road, Shanghai 200032, and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

wangbing@fudan.edu.cn

Received February 5, 2008



An efficient asymmetric synthesis of human NK-1 SP receptor antagonists (+)-CP-99,994 and (+)-L-733,060 was achieved starting from a common chiral intermediate (**5**). Our route featured the SmI<sub>2</sub>-induced reductive coupling of *N*-*tert*-butanesulfinyl imine (**7**) with aldehyde (**6**) as the key step as well as pivotal transformations of the *anti*-1,2-amino alcohol thus obtained to homochiral *syn*-1,2-amino alcohol and *syn*-1,2-diamine for the asymmetric synthesis of 2,3-disubstituted piperidines.

1,2-Amino alcohol and 1,2-diamine scaffolds are important and ubiquitous structural features in natural products and therapeutical agents possessing a wide variey of biological activities,<sup>1</sup> as well as chiral ligands and auxiliaries for asymmetric synthesis (Figure 1).<sup>2</sup> For example, (+)-CP-99,994 (1)<sup>3</sup> and (+)-L-733,060 (2)<sup>4</sup> are potent and selective human neuronkinin-1 substance P receptor antagonists. Febrifugine (3) is well-known for its antimalarial effect.<sup>5</sup> Recently, Linezolid (4)<sup>6</sup> was successfully marketed as a new antibiotic. For (+)-CP-

(3) (a) Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. *J. Med. Chem.* **1992**, *35*, 4911. (b) Rosen, T.; Seeger, T. F.; McLean, S.; Desai, M. C.; Guarino, K. J.; Bryce, D.; Pratt, K.; Heym, J.; Chalabi, P. M.; Windels, J. H.; Roth, R. W. *J. Med. Chem.* **1993**, *36*, 3197.

(4) (a) Baker, R.; Harrison, T.; Swain, C. J.; Williams, B. J. Eur. Patent, 0528495A1, 1993.
(b) Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2545.



FIGURE 1. Biologically active 1,2-diamines and 1,2-amino alcohols.

99,994 and (+)-L-733,060, their valuable biological profiles have stimulated immense interests in their syntheses.<sup>7–9</sup> To date, most asymmetric syntheses of **1** and **2** were based on chiron approach, the stereochemical outcomes of which relied more or less on substrate control. It is also noteworthy that only a handful of synthetic routes were applicable to both **1** and **2**,<sup>8d,f,h,i</sup> whereas the majority were devoted to only one of them. Hence, a general, flexible, and efficient synthesis of the two is still highly desirable.

One of the most straightforward methods to construct vicinal diamines or vicinal amino alcohols is the direct pinacol-type imine—imine or imine—aldehyde reductive coupling, respectively. Recently we have developed an efficient  $SmI_2$ -induced reductive coupling of *N*-tert-butanesulfinyl imines<sup>10</sup> with aldehydes to yield virtually enantiopure *anti*-1,2-amino alcohols.<sup>11</sup>

(7) For synthesis of racemic CP-99,994, see: (a) Desai, M. C.; Thadeio,
P. F.; Lefkowitz, S. L. *Tetrahedron Lett.* **1993**, *34*, 5831. For synthesis of racemic L-733,060, see: (b) Ref 4, (c) Tomooka, K.; Nakazaki, A.; Nakai, T. J. Am. Chem. Soc. **2000**, *122*, 408. For formal synthesis of 1 or 2, see: (d) Calvez, O.; Langlois, N. *Tetrahedron Lett.* **1999**, *40*, 7099. (e) Stadler,
H.; Bös, M. *Heterocycles* **1999**, *51*, 1067. (f) Lee, J.; Hoang, T.; Lewis, S.; Weissman, S. A.; Askin, D.; Volante, R. P.; Reider, P. J. *Tetrahedron Lett.* **2001**, *42*, 6223. (g) Bodas, M. S.; Upadhyay, P. K.; Kumar, P. *Tetrahedron Lett.* **2004**, *45*, 987. (h) Tsai, M.-R.; Chen, B.-F.; Cheng, C.-C.; Chang, N.-C. J. Org. Chem. **2005**, *70*, 1780. (i) Okada, A.; Shibuguchi, T.; Ohshima, T.; Masu, H.; Yamaguchi, K.; Shibasaki, M. Angew. Chem., Int. Ed. **2005**, *44*, 4564. (j) Li, G.; Zhao, G. Org. Lett. **2006**, *8*, 633.

(8) For synthesis of 1, see: (a) Chandrasekhar, S.; Mohanty, P. K.; Tetrahedron Lett. 1999, 40, 5071. (b) Yamakazi, N.; Atobe, M.; Kibayashi, C. Tetrahedron Lett. 2002, 43, 7979. (c) Tsuritani, N.; Yamada, K.-I.; Yoshikawa, N.; Shibasaki, M. Chem. Lett. 2002, 276. (d) Huang, P.-Q.; Liu, L.-X.; Wei, B.-G.; Ruan, Y.-P. Org. Lett. 2003, 5, 1927. (e) Atobe, M.; Yamakazi, N.; Kibayashi, C. J. Org. Chem. 2004, 69, 5595. (f) Oshitari, T.; Mandai, T. Synlett 2006, 3395. (g) Davis, F. A.; Zhang, Y.; Li, D. Tetrahedron Lett. 2007, 48, 7838. For synthesis of ent-1, see: (h) Lemire, A.; Grenon, M.; Pourashraf, M.; Charette, A. B. Org. Lett. 2004, 6, 3517. (i) Takahashi, K.; Nakano, H.; Fujita, R. Tetrahedron Lett. 2005, 46, 8927. (j) Xu, X.; Furukawa, T.; Okino, T.; Miyabe, H.; Takemoto, Y. Chem. – Eur. J. 2006, 12, 466.

(9) For synthesis of **2**, see: (a) Bhaskar, G.; Rao, B. V. *Tetrahedron Lett.* **2003**, 44, 915. (b) Yoon, Y.-J.; Joo, J. E.; Lee, K.-Y.; Kim, Y.-H.; Oh, C.-Y.; Ham, W.-H. *Tetrahedron Lett.* **2005**, 46, 739. (c) Kandula, S. R. V.; Kumar, P. *Tetrahedron: Asymmetry* **2005**, 16, 3579. (d) Cherian, S. K.; Kumar, P. *Tetrahedron: Asymmetry* **2007**, 18, 982. (e) Davis, F. A.; Ramachandar, T. *Tetrahedron Lett.* **2008**, 49, 870. (f) Ref 8d, 8f. For synthesis of *ent-2*, see: (g) Liu, L.-X.; Ruan, Y.-P. Guo, Z.-Q.; Huang, P.-Q. J. Org. Chem. **2004**, 69, 6001 and ref 8h, 8i.

<sup>&</sup>lt;sup>†</sup> Department of Chemistry, Fudan University.

<sup>&</sup>lt;sup>‡</sup> Chinese Academy of Sciences.

<sup>§</sup> Institutes of Biomedical Sciences, Fudan University.

<sup>(1)</sup> For leading reviews, see: (a) Bergmeier, S. C. *Tetrahedron* **2000**, *56*, 2561. (b) Kotti, S. R. S. S.; Timmons, C.; Li, G. *Chem. Biol. Drug Des.* **2006**, *67*, 101.

<sup>(2) (</sup>a) Ager, D. J.; Prakash, I.; Schaad, D. R. *Chem. Rev.* **1996**, *96*, 835. (b) Reetz, M. T. *Chem. Rev.* **1999**, *99*, 1121. (c) Pu, L.; Yu, H.-B. *Chem. Rev.* **2001**, *101*, 757.

<sup>(5) (</sup>a) Koepfli, J. B.; Mead, J. F.; Brockman, J. A., Jr. J. Am. Chem. Soc. **1947**, 69, 1837. (b) Koepfli, J. B.; Mead, J. F.; Brockman, J. A., Jr. J. Am. Chem. Soc. **1949**, 71, 1048.

<sup>(6)</sup> Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.; Crega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E. *J. Med. Chem.* **1996**, *39*, 673.



FIGURE 2. Retrosynthetic analysis for 1 and 2.

With this powerful tool in hand, we envisaged that both 1 and 2 could be readily synthesized from a common intermediate 5, as outlined in our retrosynthetic analysis (Figure 2). The key to this route lies in the inversion of the configuration of the hydroxyl in 5 by appropriate *N*- and *O*-nucleophiles, respectively, to furnish *syn*-1,2-diamine and *syn*-1,2-amino alcohol structural units. Conceptually, this approach complements the Sharpless asymmetric aminohydroxylation reaction<sup>12</sup> and asymmetric diamination reaction.<sup>13</sup> Moreover, it provides facile access to important 2,3-disubstituted piperidine derivatives<sup>14</sup> of all four possible configurations. Herein we wish to report an efficient asymmetric synthesis of (+)-CP-99,994 and (+)-L-733,060 based on this strategy.

The synthesis of (+)-CP-99,994 was carried out first. Reductive coupling of 4-Pivaloxybutanal (6)<sup>15</sup> with (*R*)-Phenyl *N-tert*-butanesulfinyl imine (7) afforded 5 in 78% yield and excellent *ee*.<sup>16</sup> In view of the difficulty associated with nucleophilic substitution at the C-3 of piperidine,<sup>7d</sup> we decided to invert the hydroxy of 5 to the required configuration at the early stage of the synthesis, that is, before the formation of the piperidine ring. When 5 was subject to conventional Mitsunobu condition (Ph<sub>3</sub>P, DEAD, (PhO)<sub>2</sub>PON<sub>3</sub>)<sup>17</sup> or the routine two-step sequence (MsCl/Et<sub>3</sub>N, then NaN<sub>3</sub>/DMF) to introduce the azide function, complex mixtures resulted due to participation of the electronrich sulfinyl oxygen. Oxidation of the sulfinyl to sulfonyl<sup>18</sup> did not improve the situation. Thus, the chiral auxiliary was removed under acidic conditions, and the resulting amine was protected with Boc<sub>2</sub>O to furnish **9** in 96% yield.

Mesylation and subsequent azide displacement proceeded smoothly to afford compound 10 in 82% yield with inversion

(12) (a) Li, G.; Chang, H.-T.; Sharpless, K. B. Angew. Chem., Int. Ed. Engl. **1996**, 35, 451. (b) Bruncko, M.; Schlingloff, G.; Sharpless, K. B. Angew. Chem., Int. Ed. Engl. **1997**, 36, 1483.

(13) (a) Muñiz, K.; Nieger, M. Synlett 2003, 211. (b) Muñiz, K.; Nieger,
 M.; Mansikkamäiki, H. Angew. Chem., Int. Ed. 2003, 42, 5958. (c) Du, H.;
 Yuan, W.; Zhao, B.; Shi, Y. J. Am. Chem. Soc. 2007, 129, 11688.

(14) For related reviews, see: (a) Buffat, M. G. P. *Tetrahedron* **2004**, *60*, 1701. (b) Weintraub, P. M.; Sabol, J. S.; Kane, J. M.; Borcherding, D. R. *Tetrahedron* **2003**, *59*, 2953.

(15) Rozema, M. J.; Sidduri, A.; Knochel, P. J. Org. Chem. 1992, 57, 1956.

(16) The *ee* of compound **5** (>99%) was determined by chiral HPLC analysis of compound **9** and **14**, see also ref 11. Diastereoselectivity (>90: 10) was estimated by NMR of the crude product. The minor diastereomers were removed by flash column chromatography or recrystallization (87-92% recovery).

(17) (a) Lal, B.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. *Tetrahedron Lett.* **1977**, *23*, 1977. (b) Mitsunobu, O. *Synthesis* **1981**, 1.

SCHEME 1. Total Synthesis of (+)-CP-99,994



of configuration. Deblocking of Piv with NaOMe, mesylation of the terminal hydroxyl and ring closure (NaH, DMF) gave 2,3-disubstituted piperidine derivative **11** in satisfactory yield. The azide function was reduced by hydrogenation, and the primary amine intermediate underwent mono-alkylation with 2-methoxybenzyl chloride to furnish **12** (77%) cleanly, without the contamination of a substantial amount of 2-methoxybenzyl alcohol inevitably formed in the alternative reductive amination using NaBH<sub>3</sub>CN. Removal of *N*-Boc protection under acidic condition completed the synthesis of (+)-(2*S*,3*S*)-CP-99,994 (**1**), whose spectral data were in agreement with the literature (Scheme 1).<sup>8d,f</sup> The overall yield is 46% in 10 steps under 5 operations from **5**.



Total synthesis of (+)-L-733,060 along the same line was then persued. The direct inversion of the hydroxyl in substrates such as compound **9** with *O*-nucleophiles has not been previously established, and this proved to be non-trivial.<sup>19</sup> Initial attemps to displace the mesylate of **9** with *O*-nucleophiles such as AcOK in DMF resulted in unsatisfactory yield (<30%), due partly to the instability of the mesylate at elevated temperatures and partly to the bulk of the *N*-Boc protection which might favor other reaction pathways over the substitution by the weakly nucleophilic acetate anion (eq 1). Mitsunobu reaction employing several recent modifications<sup>20</sup> was also unsuccessful.

Since all these intermolecular reactions failed to work, we then looked at the possibility of inverting the hydroxyl in an intramolecular manner (Scheme 2). Starting from chiral building block **5**, removal of the chiral auxiliary followed by selective N-acylation<sup>11</sup> with 4-methoxy-benzoic anhydride afforded amide

<sup>(10)</sup> For an overwiew of *N-tert*-butanesulfinyl imines in asymmetric synthesis, see: Ellman, J. A.; Owens, T. D.; Tang, T. P. Acc. Chem. Res. **2002**, *35*, 984.

<sup>(11)</sup> Zhong, Y.-W.; Dong, Y.-Z.; Fang, K.; Izumi, K.; Xu, M.-H.; Lin, G.-Q. J. Am. Chem. Soc. 2005, 127, 11956.

<sup>(18)</sup> Sun, P.; Weinreb, S. M.; Shang, M. J. Org. Chem. 1997, 62, 8604.
(19) Inversion of syn-1,2-amino alcohols to anti-1,2-amino alcohols has been reported using Mitsunobu reaction: Lipshutz, B. H.; Miller, T. A. Tetrahedron Lett. 1990, 31, 5253.

<sup>(20) (</sup>a) Saiah, M.; Bessodes, M.; Antonakis, K. *Tetrahedron Lett.* **1992**, 33, 4317. For recent reviews, see: (b) But, T. Y. S.; Toy, P. H. *Chem.*-*Asian J.* **2007**, 2, 1340. (c) Dembinski, R. *Eur. J. Org. Chem.* **2004**, 2763.





SCHEME 3. Total Synthesis of (+)-L-733,060



14 (88%). To our delight, upon treatement of 14 with MsCl/  $Et_3N$ <sup>21</sup> oxazoline **15** was obtained smoothly in 85% yield, with complete inversion of configuration at C-2. The stereochemistry of the product 15 was unambiguously established by NOE experiment. Compared to methods employing addition to or reduction of carbonyl, the present approach is free of racemization or epimerization since there is no involvement of  $\alpha$ -position of carbonyl. Reductive ring-opening of oxazoline (NaBH<sub>3</sub>CN, HOAc, 40 °C)<sup>22</sup> gave syn-1,2-amino alcohol 16 in excellent yield. Next, selective O-alkylation provided 17 uneventfully (82%). Conversion of 17 to piperidine 18 was achieved by sequential removal of Piv. selective O-mesulation thanks to the steric demand of PMB, and spontaneous ringclosure without using strong bases such as NaH (78%). However, the removal of N-PMB of 18 encountered tremendous difficulty. Although CAN and DDQ led to complex reactions in low yields (15-35%), 18 was inert toward 1-chloroethyl chloroformate.<sup>23</sup> Attempted hydrogenolysis with Pd catalysts under both neutral<sup>24</sup> and acidic<sup>25</sup> conditions was also unfruitful.

In this connection, removal of *N*-PMB of **16** (H<sub>2</sub>, Pd(OH)<sub>2</sub>/ C, MeOH), followed by *N*-protection with Boc<sub>2</sub>O, circumvented the above difficulty (79%) (Scheme 3). Selective *O*-benzylation of **19** was achieved using NaH (1.0 equiv) as base and TBAI as catalyst to suppress oxazolidone formation (83%). Routine deprotection of Piv and ring-closure gave *N*-Boc protected piperidine **21** (77%). Removal of *N*-Boc afforded **2**, whose spectral data were in full agreement with those reported.<sup>8d,f</sup> The overall yield is 31% in 10 steps under 7 operations from **5**.

In summary, a concise and efficient synthesis of (+)-CP-99,994 and (+)-L-733,060 was accomplished in high overall yields from a common chiral intermediate **5**. These examples illustrated the vast utility of SmI<sub>2</sub>-induced reductive coupling of *N*-tert-butanesulfinyl imines with aldehydes. Pivotal transformations of the *anti*-1,2-amino alcohols thus obtained provided easy access to a full spectrum of vicinal diamines and amino alcohols with defined stereochemistry. Further application of this versatile strategy to biologically significant molecules of more structural complexity and diversity is in progress.

## **Experimental Section**

**Compound 5.** To a cooled (-78 °C) solution of SmI<sub>2</sub> (16.9 mmol) in 60 mL THF under Ar was added dropwise a solution of **6** (1.45 g, 8.4 mmol), **7** (1.18 g, 5.6 mmol), and *t*-BuOH (1.06 mL) in THF (60 mL). The mixture was stirred for 5 h at -78 °C, quenched by saturated aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, and extracted with EtOAc (3 × 50 mL), and the combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc/Hexanes = 1:2) to afford **5** (1.68 g, 78%) as a white solid.

Mp. 87–88 °C;  $[\alpha]_D^{23}$ –26.1 (*c* 1.02, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.40–7.28 (m, 5H), 4.40 (dd, 1H, *J* = 5.4, 4.2 Hz), 4.06–3.94 (m, 3H), 3.87–3.83 (m, 1H), 2.28–2.21 (m, 1H), 1.90–1.60 (m, 2H), 1.55–1.40 (m, 1H), 1.22 (s, 9H), 1.18 (m, 1H), 1.13 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  178.5, 138.1, 128.6, 128.2, 73.1, 64.0, 62.3, 56.3, 38.7, 29.6, 27.1, 25.2, 22.6. ESI-MS *m*/*z* 384.2 (M + H<sup>+</sup>); HR-ESI-MS *m*/*z* Calcd for C<sub>20</sub>H<sub>34</sub>NO<sub>4</sub>S 384.2209, Found 384.2209.

**Compound 9.** To a solution of **5** (434 mg, 1.13 mmol) in MeOH (5 mL) was added a methanolic solution of HCl (2M, 2.3 mL) at rt, stirring was continued for 4 h, and the solution was concentrated under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL); to this was added saturated aq NaHCO<sub>3</sub> (2.5 mL) and Boc<sub>2</sub>O (295 mg, 1.36 mmol) at rt, and the mixture was stirred overnight and diluted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and the organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc/Hexanes = 1:2) to afford **9** (412 mg, 96%) as a white solid.

Mp. 88–89 °C;  $[\alpha]_D^{23}$  +10.8 (*c* 1.12, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.40–7.24 (m, 5H), 5.539–5.37 (m, 1H), 4.69–4.57 (m, 1H), 4.11–3.97 (m, 2H), 3.95–3.82 (m, 1H), 2.11 (d, 1H, *J* = 6.9 Hz), 1.88–1.40 (m, 3H), 1.41 (br s, 9H), 1.19 (m, 1H), 1.16 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  178.6, 155.5, 139.2, 128.5, 127.6, 126.5, 79.7, 73.7, 63.9, 59.2, 38.6, 29.9, 28.3, 27.1, 24.9. ESI-MS *m*/*z* 402.2 (M + Na<sup>+</sup>); HR-ESI-MS *m*/*z* Calcd for C<sub>21</sub>H<sub>34</sub>NO<sub>5</sub> (M + H<sup>+</sup>) 380.2437, Found 380.2455.

**Compound 12.** A suspension of **11** (83 mg, 0.27 mmol) and 10% Pd/C (10 mg) in MeOH (3 mL) was stirred under H<sub>2</sub> atmosphere at rt for 1 h, filtered through celite, and concentrated under reduced pressure. To a suspension of the crude amine, Cs<sub>2</sub>-CO<sub>3</sub> (264 mg, 0.81 mmol), and TBAI (20 mg, 0.054 mmol) in DMF (5 mL) was added 2-methoxybenzyl chloride (84 mg, 0.54 mmol) at rt, and the mixture was stirred for 2 days, diluted with water, and extracted with Et<sub>2</sub>O (3 × 10 mL). The combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc/Hexanes = 1:8) to afford **12** (84 mg, 77%) as a colorless oil.

 $[\alpha]_D^{23}$  +17.7 (*c* 1.00, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.57 (d, 2H, *J* = 7.5 Hz), 7.42–6.78 (m, 7H), 5.48 (br s, 1H), 3.99–3.89 (m,

<sup>(21) (</sup>a) Trost, B. M.; Lee, C. J. Am. Chem. Soc. **1998**, 120, 6818. (b) Wang, X.; Gross, P. H. J. Org. Chem. **1995**, 60, 1201.

<sup>(22)</sup> Reddy, L. R.; Saravanan, P.; Corey, E. J. J. Am. Chem. Soc. 2004, 126, 6230.

<sup>(23)</sup> Yang, B. V.; O'Rourke, D.; Li, J. Synlett 1993, 195.

<sup>(24)</sup> Rowley, M.; Leeson, P. D.; Williams, B. J.; Moore, K. W.; Baker, R. *Tetrahedron* **1992**, *48*, 3557.

<sup>(25)</sup> Trost, B. M.; Krische, M. J.; Radinov, R.; Zanoni, G. J. Am. Chem. Soc. **1996**, 118, 6297.

1H), 3.90–3.75 (AB, 2H,  $J_{AB} = 13.2$  Hz), 3.69 (s, 3H), 3.10– 3.00 (m, 1H), 2.96 (td, 1H, J = 12.9, 3.0 Hz), 1.90–1.50 (m, 4H), 1.40 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  157.5, 155.2, 139.1, 129.5, 129.2, 128.4, 128.0, 126.9, 120.3, 110.1, 79.6, 57.2, 55.0, 46.6, 39.4, 28.4, 26.8, 24.3. ESI-MS m/z 397.2 (M + H<sup>+</sup>); HR-ESI-MS m/z Calcd for C<sub>24</sub>H<sub>33</sub>N<sub>2</sub>O<sub>3</sub> 397.2491, Found 397.2476.

**Compound 1.** To a cooled (0 °C) solution of **21** (53 mg, 0.13 mmol) in MeOH (2.0 mL) was added a methanolic solution of HCl (2M, 0.25 mL, 0.5 mmol), and the mixture was stirred at rt overnight, basified with saturated aq NaHCO<sub>3</sub>, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The combined organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (aq NH<sub>3</sub>/MeOH/CHCl<sub>3</sub> = 1:10:200) to afford **1** (38 mg, 96%) as a colorless oil.

Dihydrochloride:  $[\alpha]_D^{23}$  +76.4 (*c* 0.72, MeOH). Free base:  $[\alpha]_D^{23}$  +67.3 (*c* 0.60, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.32–7.19 (m, 5H), 7.14 (td, 1H, *J* = 7.8, 1.8 Hz), 6.96 (dd, 1H, *J* = 7.2, 1.2 Hz), 6.79 (td, *J* = 7.2, 0.9 Hz), 6.66 (d, 1H, *J* = 8.1 Hz), 3.87 (d, 1H, *J* = 2.1 Hz), 3.66–3.41 (AB, 2H, *J*<sub>AB</sub> = 14.1 Hz), 3.42 (s, 3H), 3.27 (m, 1H), 2.83–2.75 (m, 2H), 2.13 (br d, 1H, *J* = 13.3 Hz), 1.93 (m, 1H), 1.77 (br s, 2H), 1.59 (m, 1H), 1.39 (br d, 1H, *J* = 13.3 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  157.6, 142.4, 129.6, 128.1, 127.8, 126.5, 126.3, 119.9, 109.8, 63.9, 54.72, 54.67, 47.7, 46.7, 28.2, 20.3. ESI-MS *m*/*z* 297.1 (M + H<sup>+</sup>); HR-ESI-MS *m*/*z* Calcd for C<sub>19</sub>H<sub>25</sub>N<sub>2</sub>O 297.1967, Found 297.1999.

**Compound 15.** To a cooled (0 °C) solution of **14** (550 mg, 1.33 mmol) and Et<sub>3</sub>N (1.2 mL, 8.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added dropwise MsCl (0.14 mL, 2.0 mmol), and the mixture was stirred at rt for 4 h and quenched with saturated aq NaHCO<sub>3</sub>, and the aq phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 15 mL). The combined organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc/Hexanes = 1:6) to afford **15** (447 mg, 85%) as a colorless oil.

 $[\alpha]_{\rm D}{}^{21} - 40.1 (c \ 0.96, \ CHCl_3); {}^{1}{\rm H} \ NMR \ (CDCl_3) \ \delta \ 7.98 \ (d, \ 2H, \ J = 9.0 \ Hz), \ 7.40 - 7.24 \ (m, \ 5H), \ 6.94 \ (d, \ 2H, \ J = 9.0 \ Hz), \ 4.87 \ (d, \ 1H, \ J = 6.9 \ Hz), \ 4.48 \ (m, \ 1H), \ 4.14 \ (m, \ 2H), \ 3.86 \ (s, \ 3H), \ 1.95 - 1.80 \ (m, \ 4H), \ 1.18 \ (s, \ 9H); \ {}^{13}{\rm C} \ NMR \ (CDCl_3) \ \delta \ 178.5, \ 163.8, \ 162.3, \ 142.4, \ 130.2, \ 128.7, \ 127.6, \ 126.7, \ 120.1, \ 113.7, \ 87.2, \ 75.7, \ 63.8, \ 55.4, \ 38.7, \ 31.8, \ 27.1, \ 24.8. \ ESI-MS \ m/z \ 396.2 \ (M + \ H^+); \ HR-ESI-MS \ m/z \ Calcd \ for \ C_{24}H_{30}NO_4 \ 396.2175, \ Found \ 396.2210.$ 

**Compound 16.** To a solution of **15** (403 mg, 1.02 mmol) in HOAc (4.0 mL) was added carefully NaBH<sub>3</sub>CN (190 mg, 3.06 mmol), and the solution was stirred at 45  $^{\circ}$ C overnight, cooled to

rt, diluted with water, basified by adding solid  $Na_2CO_3$ , and extracted with EtOAc (3 × 25 mL). The combined organic layer was washed with water and brine, dried ( $Na_2SO_4$ ), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc/Hexanes = 1:2 to 1:1) to afford **16** (366 mg, 90%) as a colorless oil.

 $[α]_D^{21}$  +45.8 (*c* 1.16, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.38-7.24 (m, 3H), 7.21-7.13 (m, 4H), 6.83 (d, 2H, *J* = Hz), 3.95 (t, 2H, *J* = 6.6 Hz), 3.78 (s, 3H), 3.64-3.42 (AB, 2H, *J*<sub>AB</sub> = 12.6 Hz), 3.60-3.52 (m, 1H), 3.30 (d, *J* = 9.0 Hz), 1.86-1.69 (m, 1H), 1.67-1.51 (m, 1H), 1.30-1.17 (m, 2H), 1.05 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 178.4, 158.7, 140.6, 131.8, 129.4, 128.7, 127.6, 127.5, 113.8, 73.8, 67.8, 64.0, 55.2, 50.4, 38.6, 29.6, 27.0, 24.9. ESI-MS *m*/*z* 400.2 (M + H<sup>+</sup>); HR-ESI-MS *m*/*z* Calcd for C<sub>24</sub>H<sub>34</sub>NO<sub>4</sub> 400.2488, Found 400.2486.

**Compound 2.** To a cooled (0 °C) solution of **21** (67 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added dropwise TFA (0.10 mL, 1.3 mmol), and the mixture was stirred at rt overnight, quenched with saturated aq NaHCO<sub>3</sub>, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The combined organic layer was washed with brine, dried (Na<sub>2</sub>-SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (MeOH/ CHCl<sub>3</sub> = 1:9) to afford **2** (50 mg, 93%) as a colorless oil.

Hydrochloride: Mp. 215–217 °C;  $[\alpha]_D^{23}$ +87.5 (*c* 0.74, MeOH); Free base:  $[\alpha]_D^{25}$ +73.9 (*c* 0.64, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.69 (br s, 1H), 7.44 (br s, 2H), 7.40–7.22 (m, 5H), 4.52 (d, 1H, *J*<sub>AB</sub> = 12.5 Hz), 4.13 (d, 1H, *J*<sub>AB</sub> = 12.5 Hz), 3.84 (d, 1H, *J* = 1.2 Hz), 3.68 (d, 1H, *J* = 1.5 Hz), 3.29 (dt, 1H, *J* = 12.2, 2.1 Hz), 2.85 (ddd, 1H, *J* = 12.5, 12.5, 3.1 Hz), 2.22 (br d, 1H, *J* = 13.7 Hz), 1.88 (m, 1H), 1.76–1.64 (m, 1H), 1.53 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  141.9, 141.2, 131.2 (q, *J* = 32.6 Hz), 128.1, 127.4, 127.1, 126.7, 123.2 (q, *J* = 271 Hz), 121.1 (m), 77.3, 70.0, 64.2, 47.1, 28.4, 20.5. ESI-MS *m*/*z* 404.0 (M + H<sup>+</sup>); HR-ESI-MS *m*/*z* Calcd for C<sub>20</sub>H<sub>20</sub>F<sub>6</sub>NO 404.1449, Found 404.1498.

Acknowledgment. Financial support from the National Natural Science Foundation of China (20602008) and Fudan University (EYH1615003, EYH1615004) is gratefully acknowledged.

Supporting Information Available: Experimental procedures, characterization data, <sup>1</sup>H and <sup>13</sup>C NMR spectra for compounds 5, 9–12, 1, 14–16, 19–21, and 2. This material is available free of charge via the Internet at http://pubs.acs.org.

JO8002979